Evotec’s White Paper Series: From Academic Concept to Commercial Reality: How to Accelerate Translational Drug Discovery

Published on : 14th February 2024

Discover more about the way-markers for a successful translational roadmap from the investor’s perspective

Singapore venture creation group 65LAB funds novel biologics project from National University of Singapore targeting lung diseases

65LAB, a unique partnership of global investors ClavystBio, Leaps by Bayer, Lightstone Ventures, Polaris Partners and the Polaris Innovation Fund alongside Evotec, has funded

65LAB awards US$1.5 million to Duke-NUS platform to advance antifibrotic drug discovery

Recipient Professor Enrico Petretto from Duke-NUS is spearheading groundbreaking research to develop new drugs for lung disease and uncover new therapeutic targets for kidney

65LAB and Duke-NUS award US$1.85 million to combat chronic inflammation

Recipient Associate Professor Lena Ho spearheads groundbreaking research to develop first-in-class therapeutics to target inflammatory diseases Collaboration between 65LAB and Duke-NUS aims to advance